Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

tudy of Voreloxin and Cytarabine Indicates Activity of Combination Regimen

Preliminary results were also presented today from Sunesis' ongoing dose-escalating Phase 1b clinical trial evaluating voreloxin in combination with cytarabine, the current standard of care in patients with relapsed and/or refractory AML. The Phase 1b trial is designed to evaluate the safety and tolerability, and to provide a preliminary assessment of anti-leukemic activity, of escalating doses of voreloxin when administered on days one and four with a fixed dose of 400 mg/m2/day of cytarabine given as a continuous infusion for five days. Of twelve evaluable patients in the first three cohorts, three patients have achieved CRs (one at 20 mg/m2 of voreloxin and two at 34 mg/m2 of voreloxin). Six patients were enrolled in cohort 4 (50 mg/m2 of voreloxin), and no dose limiting toxicities have been observed thus far at this dose. Patients are now being enrolled in cohort 5 at 70 mg/m2 of voreloxin. Voreloxin pharmacokinetics have so far been unaffected by the combination with cytarabine.

"We are very pleased by the interim results reported today from our Phase 1b combination study of voreloxin with cytarabine. We look forward to reporting results from this study later in the year, including CR rates at 50 mg/m2 and higher dose levels of voreloxin," continued Dr. Michelson.

These data were presented today in a poster titled "Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients >/= 60 Years Old Compared to <60 Years Old: Results of a Phase 1b Study" (Abstract #0515) at the 13th Congress of the European Hematology Association. A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally re
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 ... ) has announced the addition of ... American Automated External Defibrillators (AED) Market" ... http://photos.prnewswire.com/prnh/20130307/600769) ,The report North American Automated ... market of devices based upon following ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market leader ... LeadingAge Annual Meeting in Nashville, TN. ... the market leading solution for onsite, remote medication dispensing. ... care facilities to safely and securely dispense medication onsite, ... first dose, helps ensure that the correct medication gets ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
... Feb. 21, 2012 ConvaTec, a world-leading developer and ... care, today announces that Ken Berger will assume the ... the ConvaTec Board of Directors. Berger joins ... last ten years, most recently as Senior Vice President ...
... Feb. 21, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ... overview at the Citi Global Healthcare Conference on February 27, ... New York City.   The live and archived ... of Events" in the Idenix Investor Center at ...
Cached Medicine Technology:ConvaTec Announces the Appointment of Ken Berger to the Position of CEO Effective March 6, 2012 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... Nearly one in three women who have breast cancer ... additional surgery after the tumor is evaluated by a pathologist. ... Cancer Center cuts that number drastically by having pathologists on-site ... immediately after they are removed. Meanwhile, the surgeon and patient ...
... News) -- Drug-free recovery housing and day treatment programs ... who have gone through detoxification will be able to ... abuse includes both the use of illegal drugs such ... such as OxyContin, Vicodin and Percocet. Opioid addicts ...
... alone, approximately 6 million people suffer from an irregular ... with age, it is predicted that 15.9,million Americans will ... of AF is stroke, but,a new device from Boston ... Atritech, now part of Boston Scientific, developed the WATCHMAN ...
... MONDAY, Feb. 27 (HealthDay News) -- Many people with stable ... work just as well, a new study suggests. The ... a clogged artery. As many as three-quarters of these operations ... professor of medicine at Stony Brook University Medical Center in ...
... A great deal has been learned in the ten years ... (WHI). Hormone therapy (HT) remains the most effective treatment available ... a growing body of evidence that formulation, route of administration, ... effects. It is essential to evaluate a personal ...
... the country tripled to nearly three per year between 1994 ... 15 years, according to an analysis of weather conditions and ... Georgia researchers. The scientists built a detailed database ... well as the height, weight and position for 58 football ...
Cached Medicine News:Health News:Fewer women need repeat breast cancer surgeries with new service at University of Michigan 2Health News:Drug-Free Housing Helps Heroin, Oxycontin Addicts Recover 2Health News:Stroke-preventing technology demonstrated in JoVE 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 3Health News:The North American Menopause Society (NAMS) reassures many women 2Health News:Deaths triple among football players, morning temperatures thought to play a role 2